Ras as a therapeutic target in hematologic malignancies.

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• RAS proteins (N-Ras, K-Ras, H-Ras) are G proteins acting as cellular on/off switches, regulating proliferation, survival, and differentiation.
• Mutated RAS proteins are constitutively active, driving cancer through downstream signaling pathways like Raf/MEK/ERK and PI3K/AKT.
• RAS pathways are implicated in hematologic malignancies, often downstream of receptor tyrosine kinases such as BCR-ABL.

Purpose of the Study:

• To review Ras biology, its signaling pathways, and its therapeutic potential in hematologic malignancies.
• To discuss the limitations of current Ras inhibitors, particularly farnesyl transferase inhibitors (FTIs).
• To explore novel therapeutic strategies targeting Ras proteins.

Main Methods:

• Review of existing literature on Ras protein function, signaling, and therapeutic targeting.
• Discussion of post-translational modifications required for Ras membrane localization and activity.
• Analysis of the mechanism of action for farnesyl transferase inhibitors (FTIs) and alternative inhibitors.

Main Results:

• RAS proteins require post-translational modification for membrane anchoring and biological activity.
• FTIs block farnesyl-transferase (FTase) but their effectiveness is limited by compensatory geranylgeranylation.
• S-trans, trans-farnesylthiosalicylic acid demonstrates in vitro activity by disrupting Ras membrane localization.

Conclusions:

• Targeting Ras signaling pathways remains a critical strategy in hematologic malignancies.
• Alternative inhibitors that dislodge Ras proteins from membranes offer a promising therapeutic approach.
• Further research into Ras biology and novel inhibitors is essential for effective cancer treatment.